Gut microbiota and inflammation in chronic kidney disease patients.
Gut microbiota and inflammation in chronic kidney disease patients.
复制标题
DOI：
10.1093/ckj/sfv026
复制
发表时间：
2015-06
影响因子：
4.6
通讯作者：
Fouque D
中科院分区：
文献类型：
--
作者：
Mafra D;Fouque D
炎症是一种多因素的表型，在慢性肾脏疾病中与患者的不良预后相关。最近，CKD患者肠道微生物区系组成和肠道屏障的改变与炎症和氧化应激有关。Vanhold和Glorieux最近批判性地回顾了[Clin Kidney J(2015)8(2)：168-179]肠道微生物区系在尿毒症毒素产生中的作用及其治疗意义的当前理解。我们现在处于什么位置？肠肾串扰的基本机制仍需阐明。此外，应评估调节肠道微生物区系以减少慢性肾脏疾病尿毒症毒素产生和炎症的治疗策略的有效性和安全性。最后，在纳入常规临床实践之前，应该证明这些策略对硬结果的影响。
Inflammation is a multifactorial phenotype that in chronic kidney disease is associated with adverse patient outcomes. Recently, alterations in gut microbiota composition and intestinal barrier have been associated with inflammation and oxidative stress in CKD patients. Vanholder and Glorieux recently critically reviewed [Clin Kidney J (2015) 8 (2): 168-179] the current understanding of the role of gut microbiota in the production of uraemic toxins and the therapeutic implications. Where do we stand now? The basic mechanisms of the gut-kidney crosstalk must still be clarified. In addition, the efficacy and safety of therapeutic strategies to modulate the gut microbiota in order to decrease uraemic toxin production and inflammation in chronic kidney disease should be evaluated. Finally, an impact of such strategies on hard outcomes should be demonstrated before incorporation into routine clinical practice.